Chimerix announced the presentation of final data from the AdVise trial of brincidofovir for the treatment of adenovirus (AdV) infection...
Chimerix, Inc. has announced preliminary data for its investigational antiviral brincidofovir (BCV, CMX001) showing improved survival for patients with Adenovirus...
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support.
AbbVie Inc. and Tentarix Biotherapeutics announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology
Ferring Pharmaceuticals announced the FDA approved Adstiladrin (nadofaragene firadenovec-vncg), a novel adenovirus vector-based gene therapy, for the treatment of adult patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors
Advanced care planning (ACP) is a process of reflection and communication about a person's values and wishes concerning future health issues and personal care preferences in the event that one becomes incapable of consenting to or refusing treatment or other care.
One puzzle in the bladder cancer diagnosis is the disproportional relationship between genders. Males are more likely to be diagnosed with bladder cancer whereas females typically are diagnosed with more adverse disease and worse prognosis, which has led to speculation of the potential role of sex hormones and their receptors in this disease.
Containing relevant Learning Zones, guidelines, trials and news.
The UK National Institute for Health and Care Excellence (NICE) has conditionally recommended Tagrisso (osimertinib), from AstraZeneca, as an option...
The European Commission has granted conditional marketing authorization to adagrasib (Krazati) for use in adult patients with advanced non–small cell lung cancer (NSCLC) harboring a KRAS G12C mutation whose disease progressed following at least 1 prior systemic treatment